UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D. **SECTION 4(6), AND/OR** UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL

1769021	OMB Number: Expires: July 3 Estimated avera hours per form.	1, 2008 age burden
URITIES TO THE PROPERTY OF T	SEC US Prefix	SE ONLY Serial
EXEMITION &	DATER	ECEIVED

Name of Offering (☐ check if this is an		-	_					
Offering of Series C Preferred Stock	and the underlying shares of	commo	n stock issuable upor	conversion of t	he Seri	es C Prefe	erred Stock	k
Filing Under (Check box(es) that apply)	: Rule 504		☐ Rule 505	➤ Rule 506		☐ Secti	on 4(6)	☐ ULOE
Type of Filing:		X	New Filing			Amenda	ment	
	A. B.	ASIC IE	ENTIFICATION DA	ATA				
1. Enter the information requested ab	out the issuer						,	
Name of Issuer (check if this is an ar	mendment and name has chang	ed, and	indicate change.)	.				
Portola Pharmaceuticals, Inc.								
Address of Executive Offices	(Number and	Street,	City, State, Zip Code)	Telephone Nu	ımber (Includir		1811 11114 8118 1111 1111 1111 1111 111
270 East Grand Avenue, Suite 22, Sou	uth San Francisco, CA 9408)			0-244-6		116144 ((())	
Address of Principal Business Operation	ns (Number and Street, City, S	tate, Zip	Code)	Telephone Nu	ımber (Includir	1,000 1100 1000 1	
(a dilicial non Excess onless)			PROCES	DED				08052918
Brief Description of Business			JUL 252	ያበበዩ አ				
Research and Development			JUL # 8 &	-000 P				
Type of Business Organization			THOMOONE	DEI ITEDS				
	☐ limited partnership, alr	eady for	WALIONION I	KEUIEKS		other (ple	ase specify	·):
☐ business trust	☐ limited partnership, to							
		•		Year				
Actual or Estimated Date of Incorporati	on or Organization:	•	09	2003	[32]	Actual	r) Estimated
Jurisdiction of Incorporation or Organiz	ation: (Enter two-letter U.S	S. Postal	Service abbreviation t	for State:	_	, , , , , , , , , , , , , , , , , , , ,	_	r millione.
			r foreign jurisdiction)				E	PΕ

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION DATA

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. inter'the information requested for the following:

- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- Each general and managing partner of partnership issuers.

Check Box(es) that Apply:	☐ Promoter	Beneficial Owner	Executive Officer	☑ Director	General and/or Managing Partner					
Full Name (Last name first, if individual) Homey, Charles J.										
Business or Residence Address (Number and Street, City, State, Zip Code) 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080										
Check Box(es) that Apply:	Promoter	☒ Beneficial Owner	☐ Executive Officer	☐ Director	General and/or Managing Partner					
Full Name (Last	name first, if individual)									
	Living Trust of Robert M. and Sidence Address (Number addr	nd Carroll Anna Scarboroug	h of May 1995							
	Court, Half Moon Bay, CA									
Check Boxes that Apply:	Promoter	■ Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner					
Full Name (Last Phillips, David	name first, if individual) R.			<u> </u>						
	idence Address (Number and S I Avenue, Suite 22, South Sar	-								
Check Boxes that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	General and/or Managing Partner					
Full Name (Last Bird, Jeff	name first, if individual)									
	idence Address (Number and S Ventures, 755 Page Mill Road	treet, City, State, Zip Code) d, Suite A-200, Palo Alto, CA	94306							
Check Boxes that Apply:	Promoter	₭ Beneficial Owner	☐ Executive Officer	☑ Director	General and/or Managing Partner					
Full Name (Last Hirsch, Russell	name first, if individual)		•							
	idence Address (Number and Sentures, 435 Tasso Street, Sui									
Check Boxes that Apply:	☐ Promoter	☑ Beneficial Owner	☐ Executive Officer	☑ Director	General and/or Managing Partner					
Full Name (Last Galakatos, Nic	name first, if individual) holas									
	idence Address (Number and S entures, 111 Huntington Ave	Street, City, State, Zip Code) nue, 31st Floor, Boston, MA	02199							
Check Boxes that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☒ Director	General and/or Managing Partner					
Full Name (Last George, Jean	name first, if individual)									
Business or Res	idence Address (Number and S									
		00 Winter Street, Suite 3700,		i						
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	☐ General and/or Managing Partner					
Full Name (Last Frazier, Alan	name first, if individual)									
Business or Res	idence Address (Number and			·						
c/o Frazier Hea	althcare IV, LP, 601 Union S	treet, Suite 3300, Seattle, WA	98101							

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- Each general and managing partner of partnership issuers.

	,				···- <u> </u>					
Check Box(es) that	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner					
Apply:	C (C)(1)				· ·					
Full Name (Last name first, if individual) Prospect Venture Partners II, L.P. and affiliated entities										
Business or Residence Address (Number and Street, City, State, Zip Code) 435 Tasso Street, Suite 200, Palo Alto, CA 94301										
Check	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or					
Box(es) that					Managing Partner					
Apply:										
	t name first, if individual) ures III-QP, L.P.									
	idence Address (Number and									
	n Avenue, 31st Floor, Boston	, MA 02199								
Check Boxes that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	General and/or Managing Partner					
Full Name (Las	name first, if individual)	·····		·						
Phillips, Peggy										
	idence Address (Number and				·					
	d Avenue, Suite 22, South Sa									
Check Boxes that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner					
Full Name (Las	t name first, if individual)		<u> </u>							
Olson, Carol										
	idence Address (Number and									
	d Avenue, South San Francis									
Check Boxes that Apply:	☐ Promoter	☐ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner					
Full Name (Las Dier, Mardi	t name first, if individual)									
Business or Res	idence Address (Number and	Street, City, State, Zip Code)	-							
270 East Gran	d Avenue, South San Francis	sco, CA 94080								
Check Boxes	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	☐ General and/or					
that Apply:					Managing Partner					
•	t name first, if individual)									
Champsi, Fara			· · · · · · · · · · · · · · · · · · ·							
	sidence Address (Number and ers, One Embarcadero Cente	Street, City, State, Zip Code) er, Suite 4050, San Francisco,	CA 94111							
Check Boxes	Promoter	☐ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or					
that Apply:					Managing Partner					
Full Name (Las Wolff, Ward	t name first, if individual)									
	idence Address (Number and d Avenue, South San Franci		· · · · · ·							
Check	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or					
Box(es) that					Managing Partner					
Apply: Full Name (Las	t name first, if individual)									
, un mante (Las	i mante mon, ir murridum)									
Business or Res	idence Address (Number and	Street, City, State, Zip Code)	· · · · · · · · · · · · · · · · · · ·		· <u>-</u> .					
		·								

B. INFORMATION ABOUT OFFERING													
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?											>_X	
2.	. What is the minimum investment that will be accepted from any individual?										N/A		
3.	Does the o	offering perm	nit joint owne	rship of a si	ngle unit?			••••		·····		Yes <u>X</u> No	·
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only. NONE													
Full	Name (Las	t name first,	if individual)			-	- .	****		-		
Bus	iness or Re	sidence Add	ress (Number	and Street,	City, State,	Zip Code)	-						· · · · · · · · · · · · · · · · · · ·
Nan	ne of Assoc	iated Broker	or Dealer										
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers											<u></u> ,		
(Ch	eck "All St	ates" or chec	k individual	States)			****************					***************************************	🗆 All States
[AL	J	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	(HI)	[ID]
[IL]		[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[M]	rj	[NE]	[NV]	[NH]	[[[]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	·	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	(VA)	[VA]	[WV]	[WI]	[WY]	[PR]
Full	Name (Las	st name first	, if individual)				•					
Bus	iness or Re	sidence Add	lress (Number	r and Street,	City, State,	Zip Code)							
Nar	ne of Assoc	iated Broke	r or Dealer					_					
			ted Has Solic					-		-			
(Ch	eck "All St	ates" or chec	ck individual	States)	•••••				•••••			***************************************	🗆 All States
[AL	.}	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	(FL)	[GA]	(HI)	[tD]
[IL]		[EN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[M	Γ]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	{OK]	[OR]	[PA]
[RI	<u> </u>	[SC]	[SD]	[TN]	{TX}	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]
Ful	l Name (Las	st name first	, if individual	1)									
Bus	iness or Re	sidence Ado	Iress (Number	r and Street,	City, State	Zip Code)							
Nai	ne of Assoc	ciated Broke	r or Dealer										
Sta	tes in Whic	h Person Lis	ted Has Solic	ited or Inten	ds to Solici	t Purchasers		,,					
(Ch	eck "All St	ates" or che	ck individual	States)					***************************************				🗆 All States
[AI	- l	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	(DE)	[DC]	(FL)	[GA]	(HI)	[ID]
(IL	l	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[M	TJ	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
{RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." transaction is an exchange offering, check this box 🛘 and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. Aggregate Amount Already Type of Security Offering Price Sold Debt \$ __60,000,000.33 60,000,000.33 Equity Common × Preferred Convertible Securities (including warrants)..... Partnership Interests.... Other (Specify) Total 60.000,000,33 \$ 60,000,000.33 Answer also in Appendix, Column 3, if filing under ULOE. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." Number Aggregate **Dollar Amount** Investors of Purchases \$ 60,000,000,33 Accredited Investors 0 Non-accredited Investors Total (for filings under Rule 504 only) Answer also in Appendix, Column 4, if filing under ULOE. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. Type of Dollar Amount Security Sold Type of Offering Rule 505..... Regulation A.... Rule 504 Total..... a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate. Transfer Agent's Fees Printing and Engraving Costs × 40,000,00 Legal Fees Accounting Fees Engineering Fees..... Sales Commissions (specify finders' fees separately)

Other Expenses (Identify)

Total.....

×

40,000.00

C. OFFERING PRICE, NUMBER OF	INVESTORS, EXPENSES AND	JSE OF PROCEEDS	
 Enter the difference between the aggregate offering price given in r in response to Part C – Question 4.a. This difference is the "adjuste 	esponse to Part C - Question 1 and d gross proceeds to the issuer"	total expenses furnished	\$ <u>59,960,000.33</u>
 Indicate below the amount of the adjusted gross proceeds to the issuer of the amount for any purpose is not known, furnish an estimate and payments listed must equal the adjusted gross proceeds to the issuer set 	check the box to the left of the es	timate. The total of the on 4.b above.	DT-
•		Payment to Officers, Directors, & Affiliates	Payment To Others
Salaries and fees		□ \$	□ s
Purchase of real estate		\$	□ \$
Purchase, rental or leasing and installation of machinery and equipment		□ \$	
Construction or leasing of plant buildings and facilities		 \$	\$
Acquisition of other businesses (including the value of securities involved in exchange for the assets or securities of another issuer pursuant to a merger	n this offering that may be used	□ \$	□ s
Repayment of indebtedness		□ \$	□ \$
Working capital		□ \$	★ \$ 59,960,000,33
Other (specify):		□ \$	
		□ \$	□ s
Column Totals		□ \$	59,960,000.33
Total Payments Listed (column totals added)		× \$5	9,960,000.33
	•		
D. FEI	DERAL SIGNATURE		
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange	authorized person. If this notice is	filed under Rule 505, the of its staff, the information	following signature constitutes n furnished by the issuer to any
The issuer had duly caused this notice to be signed by the undersigned duly	authorized person. If this notice is	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502.	authorized person. If this notice is Commission, upon written request	filed under Rule 505, the of its staff, the information	n furnished by the issuer to any
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc.	authorized person. If this notice is Commission, upon written request Signature	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Portola Pharmaceuticals, Inc. Name of Signer (Print or Type)	authorized person. If this notice is Commission, upon written request Signature Title of Signer (Print or Type)	of its staff, the information	n furnished by the issuer to any Date

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

-	E. STATE	SIGNATURE							
I.	Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule?								
	See Appendix, Colu	nn 5, for state response.							
2.	2. The undersigned issuer hereby undertakes to furnish to the state administrator of any state in which the notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.								
3.	3. The undersigned issuer hereby undertakes to furnish to any state administrators, upon written request, information furnished by the issuer to offerees.								
4.									
The	e issuer has read this notification and knows the contents to be true and has d	uly caused this notice to be signed on its behalf by the unders	igned duly	authorized					
per	son.								
Issu	ier (Print or Type)	Signature / / /	Date						
Por	rtola Pharmaceuticals, Inc.	James Sole	July <u>18</u> , 2	2008					
Nai	me (Print or Type)	Title (Print or Type)							
Par	mela Green	Gecretary							

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

•			**	APPENDIX				• •	
1		2	3		4				5
	Intend to sell to non-accredited investors in State (Part B-Item 1) Type of security and aggregate offering price offered in state (Part C-Item 1)			Type of investor and amount purchased in State (Part C-Item 2)				Disqualification under State ULOE (if yes, attach explanation of waiver granted (Part E-Item 1)	
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No
AL					· · · · · · · · · · · · · · · · · · ·				
AK		<u> </u>		•••					
AZ									
AR									
CA		X	\$5,500,000.35 to purchase Preferred Stock	24	\$5,500,000.35	0	0		Х
co .		Х	\$4,250,000.61 to purchase Preferred Stock	2	\$4,250,000.61	0	0	:	Х
СТ									
DE									
DC									
FL									
GA						l			
н									
ID									
IL.									
IN									
lA			-						
KS									
KY									
LA									
ME				<u> </u>					
MD									
MA		x	\$19,014,583.24 to purchase Preferred	H	\$19,014,583.24	0	0		Х
МІ			paramot Helefield						
MN									
MS									
МО									

				A PENDI	X				
1		2	3		4				5
	to non- investo	nd to sell accredited ors in State B-Item 1)	Type of security and aggregate offering price offered in state (Part C-Item 1)	Type of investor and amount purchased in State (Part C-Item 2)			Disqualification under State ULOE (if yes, attach explanation of waiver granted (Part E- Item 1)		
State	Yes	No		Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No
MT					<u>-</u>	 		_	1
NE					<u> </u>	<u> </u>			
NV									
NH					-				
lи									
NM	-				-				
NY		Х	\$18,843,505.50 to purchase Preferred	7	\$18,843,505.50	0	0		Х
NC			purchase Preferred					 	
ND									
ОН						<u> </u>			
ОК				,	_				
OR									
PA	<u> </u>								
RI		<u> </u>							
SC				··					
SD									
TN					1				
тх		Х	\$2,830,000.00 to purchase Preferred Stock	1	\$2,830,000.00	0	0		Х
UT									
VT				-					
VA									
WA		Х	\$2,356,154.71 to purchase Preferred Stock	2	\$2,356,154.71	0	0		х
wv									
WI									
WY									
PR					1	1			

